Autor(es):
Callefi, Luciana Azevedo ; Villela-Nogueira, Cristiane Alves ; de Barros Tenore, Simone ; Carnaúba-Júnior, Dimas ; Coelho, Henrique Sérgio Moraes ; Pinto, Paulo de Tarso A. ; Nabuco, Letícia Cancella ; Pessoa, Mário Guimarães ; Ferraz, Maria Lucia Cardoso Gomes ; Ferreira, Paulo Roberto Abrão ; de Lourdes Candolo Martinelli, Ana ; Chachá, Silvana Gama Florencio ; de Souza Paiva Ferreira, Adalgisa ; de Macedo Bisio, Alessandra Porto ; Brandão-Mello, Carlos Eduardo ; Álvares-Da-Silva, Mário Reis ; Reuter, Tânia ; Ivantes, Claudia Alexandra Pontes ; de Mello Perez, Renata ; Mendes-Correa, Maria Cássia Jacintho
Data: 2017
Origem: Oasisbr
Assunto(s): Protease inhibitors; Safety; Hepatitis C; Chronic; Therapeutics
Descrição
OBJECTIVE: To evaluate the effectiveness and safety of first-generation protease inhibitors for the treatment of genotype 1 hepatitis C virus-infected patients at Brazilian reference centers. METHODS: This multicenter cross-sectional study included hepatitis C virus genotype 1 monoinfected patients treated with Peg-interferon, ribavirin, and either boceprevir (n=158) or telaprevir (n=557) between July 2013 and April 2014 at 15 reference centers in Brazil. Demographic, clinical, virological, and adverse events data were collected during treatment and follow-up. RESULTS: Of the 715 patients, 59% had cirrhosis and 67.1% were treatment-experienced. Based on intention-to-treat analysis, the overall sustained viral response was 56.6%, with similar effectiveness in both groups (51.9% for boceprevir and 58% for telaprevir, p=0.190). Serious adverse events occurred in 44.2% of patients, and six deaths (0.8%) were recorded. Cirrhotic patients had lower sustained viral response rates than non-cirrhotic patients (46.9% vs. 70.6%, p
